[go: up one dir, main page]

AR040126A1 - Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento - Google Patents

Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento

Info

Publication number
AR040126A1
AR040126A1 ARP030101854A ARP030101854A AR040126A1 AR 040126 A1 AR040126 A1 AR 040126A1 AR P030101854 A ARP030101854 A AR P030101854A AR P030101854 A ARP030101854 A AR P030101854A AR 040126 A1 AR040126 A1 AR 040126A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
ring
cycloalkyl
integer selected
Prior art date
Application number
ARP030101854A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0212401A external-priority patent/GB0212401D0/en
Priority claimed from GB0230053A external-priority patent/GB0230053D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR040126A1 publication Critical patent/AR040126A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Composiciones farmacéuticas que lo comprenden y su uso para preparar medicamentos útiles para el tratamiento de un estado que requiere la modulación de un receptor de dopamina. Los compuestos son útiles en terapia, en particular como agentes antipsicóticos. Reivindicación 1: Un compuesto de fenilsulfonilo caracterizado porque tiene la fórmula (1) en la cual: A y B representan los grupos -(CH2)m- y -(CH2)n-, respectivamente; R1 representa hidrógeno o alquilo C1-6; R2 representa hidrógeno, halógeno, hidroxi, ciano, nitro, hidroxi-alquilo C1-6, trifluorometilo, trifluorometoxi, alquilo C1-6, alcoxi C1-6, fluoroalcoxi C1-6, -(CH2)p-cicloalquilo C3-6, -(CH2)p-O-cicloalquilo C3-6, -CO-alquilo C1-6, -SO2-alquilo C1-6, -SO-alquilo C1-6, -S-alquilo C1-6, -CO2-alquilo C1-6, -CO2NR5R6, -SO2NR5R6, -(CH2)pNR5R6, -(CH2)pNR5COR6, un anillo de arilo opcionalmente sustituido, un anillo de heteroarilo opcionalmente sustituido o un anillo de heterociclilo opcionalmente sustituido; R3 representa un anillo de arilo opcionalmente sustituido o un anillo heteroarilo opcionalmente sustituido; R4 representa hidrógeno, hidroxi, alquilo C1-6, alcoxi C1-6, trifluorometilo, trifluorometoxi, halógeno, -OSO2CF3, -(CH2)p-cicloalquilo C3-6, -(CH2)qO-alquilo C3-6 o -(CH2)pO-cicloalquilo C3-6; R5 y R6 representan cada uno independientemente hidrógeno, alquilo C1-6 o, junto con el átomo de nitrógeno u otros a los que están unidos, forman un anillo de azacicicloalquilo o un anillo de azacicloalquilo sustituido con oxo; Z representa -(CH2)rX- en la que el grupo -(CH2)r- está unido a R3, o -X(CH2)r- en donde X está unido a R3 y en donde cualquiera de los grupos -CH2- puede estar opcionalmente sustituidos con uno o más grupos alquilo C1-6; X representa oxígeno, -NR7 o -CH2-, en los que el grupo -CH2- puede estar opcionalmente sustituido con uno o más grupos alquilo C1-6; R7 representa halógeno o alquilo C1-6; m y n representan independientemente un número entero seleccionado entre 1 y 2; p representa independientemente un número entero seleccionado entre 0, 1, 2 y 3; q representa independientemente un número entero seleccionado entre 1, 2 y 3; r representa independientemente un número entero seleccionado entre 0, 1 y 2; o una sal o solvato farmacéuticamente aceptable del mismo.
ARP030101854A 2002-05-29 2003-05-27 Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento AR040126A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0212401A GB0212401D0 (en) 2002-05-29 2002-05-29 Compounds
GB0230053A GB0230053D0 (en) 2002-12-23 2002-12-23 Compounds

Publications (1)

Publication Number Publication Date
AR040126A1 true AR040126A1 (es) 2005-03-16

Family

ID=29585827

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101854A AR040126A1 (es) 2002-05-29 2003-05-27 Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento

Country Status (25)

Country Link
US (2) US7504392B2 (es)
EP (1) EP1511727B1 (es)
JP (1) JP4268126B2 (es)
KR (1) KR20050013196A (es)
AR (1) AR040126A1 (es)
AT (1) ATE354566T1 (es)
AU (1) AU2003232846B9 (es)
BR (1) BR0311315A (es)
CA (1) CA2486962A1 (es)
CY (1) CY1107053T1 (es)
DE (1) DE60311986T2 (es)
DK (1) DK1511727T3 (es)
ES (1) ES2279965T3 (es)
IL (1) IL165330A0 (es)
IS (1) IS2482B (es)
MX (1) MXPA04011945A (es)
MY (1) MY133587A (es)
NO (1) NO330118B1 (es)
NZ (1) NZ536694A (es)
PL (1) PL374081A1 (es)
PT (1) PT1511727E (es)
RU (1) RU2327690C2 (es)
SI (1) SI1511727T1 (es)
TW (1) TWI281914B (es)
WO (1) WO2003099786A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY133587A (en) 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use
JP2005533809A (ja) * 2002-06-19 2005-11-10 シェーリング　コーポレイション カンナビノイドレセプタアゴニスト
GB0319235D0 (en) * 2003-08-15 2003-09-17 Glaxo Group Ltd Novel compounds
GB0327738D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compound
GB0327741D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
GB0327737D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
GB0327740D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
WO2006105345A2 (en) * 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Compositions and methods for the control, prevention, and treatment of obesity and eating disorders
GB0505437D0 (en) * 2005-03-17 2005-04-20 Merck Sharp & Dohme Therapeutic agents
GB0505725D0 (en) * 2005-03-19 2005-04-27 Merck Sharp & Dohme Therapeutic agents
GB0510599D0 (en) * 2005-05-24 2005-06-29 Glaxo Group Ltd Novel compounds
GB0603087D0 (en) * 2006-02-15 2006-03-29 Glaxo Group Ltd Novel use
WO2007149728A2 (en) * 2006-06-20 2007-12-27 Alcon Research, Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
TWI399376B (zh) * 2006-08-04 2013-06-21 Merz Pharma Gmbh & Co Kgaa 經取代之吡唑並嘧啶類，製備彼等之方法及彼等作為藥物之用途
ES2545275T3 (es) * 2008-11-06 2015-09-09 Ventirx Pharmaceuticals, Inc. Métodos de síntesis de derivados de benzazepinas
US20180228811A1 (en) * 2014-12-12 2018-08-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders
US11124497B1 (en) 2020-04-17 2021-09-21 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US11174231B1 (en) 2020-06-09 2021-11-16 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003137A1 (en) 1986-10-28 1988-05-05 Smith Kline & French Laboratories Limited Tetrahydroisoquinolin-2-yl derivatives of carboxylic acids as thromboxane a2 antagonists
EP0282287B2 (en) * 1987-03-10 1996-04-24 Lion Corporation Deodorizer
EP0285287A3 (en) * 1987-03-23 1990-08-16 Smithkline Beecham Corporation 3-benzazepine compounds for use in treating gastrointestinal motility disorders
GB8717374D0 (en) 1987-07-22 1987-08-26 Smith Kline French Lab Pharmaceutically active compounds
US5032604A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
GB9127041D0 (en) 1991-12-20 1992-02-19 Fujisawa Pharmaceutical Co New use
GB9212308D0 (en) 1992-06-10 1992-07-22 Ici Plc Therapeutic compositions
EP0747381B1 (en) 1994-02-25 2001-10-31 Banyu Pharmaceutical Co., Ltd. Carbapenem derivative
US5684195A (en) 1994-07-14 1997-11-04 G. D. Searle & Co. Method of preparing sulfmonamides from sulfones
CA2220055C (en) 1995-05-08 2001-04-24 Pfizer Inc. Dipeptides which promote release of growth hormone
DE19548785A1 (de) 1995-12-27 1997-07-03 Basf Ag Saure Polyazofarbstoffe
PL329803A1 (en) 1996-05-11 1999-04-12 Smithkline Beecham Plc Derivatives of tetrahydroisoquinoline as modulators od dopamine d receptors
JP2000517301A (ja) 1996-08-14 2000-12-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー テトラヒドロイソキノリン誘導体およびそれらの薬理学的使用
DE19638484A1 (de) 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
DE19638486A1 (de) 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
JP2001526648A (ja) 1997-04-22 2001-12-18 コセンシス・インコーポレイテッド 炭素環及びヘテロ環で置換されたセミカルバゾン及びチオセミカルバゾン、及びその使用
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
EP0937723A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
GB9804734D0 (en) 1998-03-05 1998-04-29 Pfizer Ltd Compounds
US6344486B1 (en) 1998-04-03 2002-02-05 3-Dimensional Pharmaceuticals, Inc. Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors
EP1119568B1 (en) 1998-10-09 2004-02-18 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
AR022228A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion
CN1349498A (zh) 1999-03-03 2002-05-15 宝洁公司 含有链烯基和炔基的金属蛋白酶抑制剂
AU5041300A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
EP1280777B1 (en) 2000-05-11 2005-11-23 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
US6416458B1 (en) * 2000-07-12 2002-07-09 Therion Research Inc. Therapeutic flexible magnetic sheet and method
CA2390535C (en) 2000-09-14 2008-12-02 Edmund Gene Butts Curling garment brush retainer
DE10053799A1 (de) 2000-10-30 2002-05-08 Bayer Ag Verwendung von Tetrahydroisochinolinsulfonamiden
BR0115328A (pt) 2000-11-14 2004-04-06 Smithkline Beecham Plc Derivados de tetraidro benzazepina úteis como moduladores dos receptores d3 de dopamina (agentes anti-psicóticos
EP1341765A1 (en) 2000-12-07 2003-09-10 AstraZeneca AB Therapeutic compounds
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
WO2003062205A1 (en) 2001-12-21 2003-07-31 Smithkline Beecham P.L.C. 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
WO2003068752A1 (en) 2002-02-13 2003-08-21 Glaxo Group Limited Benzenesulfonamide derivatives as antipsychotic agents
TW200306843A (en) 2002-02-13 2003-12-01 Glaxo Group Ltd Novel compounds
AU2003218660A1 (en) 2002-02-13 2003-09-04 Glaxo Group Limited Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds
GB0210762D0 (en) 2002-05-10 2002-06-19 Glaxo Group Ltd Compounds
GB0212399D0 (en) 2002-05-29 2002-07-10 Glaxo Group Ltd Compounds
MY133587A (en) 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use

Also Published As

Publication number Publication date
IS7577A (is) 2004-12-01
AU2003232846A1 (en) 2003-12-12
PT1511727E (pt) 2007-05-31
ES2279965T3 (es) 2007-09-01
US7504392B2 (en) 2009-03-17
US20050261279A1 (en) 2005-11-24
SI1511727T1 (sl) 2007-06-30
EP1511727A2 (en) 2005-03-09
JP4268126B2 (ja) 2009-05-27
BR0311315A (pt) 2005-03-01
CY1107053T1 (el) 2012-10-24
MXPA04011945A (es) 2005-03-31
WO2003099786A2 (en) 2003-12-04
NO330118B1 (no) 2011-02-21
NO20045659L (no) 2004-12-27
RU2004138588A (ru) 2005-06-27
US20080269197A1 (en) 2008-10-30
IS2482B (is) 2008-12-15
MY133587A (en) 2007-11-30
DK1511727T3 (da) 2007-06-11
AU2003232846B2 (en) 2007-02-22
KR20050013196A (ko) 2005-02-03
RU2327690C2 (ru) 2008-06-27
CA2486962A1 (en) 2003-12-04
TW200406381A (en) 2004-05-01
EP1511727B1 (en) 2007-02-21
PL374081A1 (en) 2005-09-19
TWI281914B (en) 2007-06-01
AU2003232846B9 (en) 2007-04-19
DE60311986T2 (de) 2007-10-31
NZ536694A (en) 2006-11-30
WO2003099786A3 (en) 2004-09-02
DE60311986D1 (de) 2007-04-05
JP2005531579A (ja) 2005-10-20
HK1075050A1 (en) 2005-12-02
IL165330A0 (en) 2006-01-15
ATE354566T1 (de) 2007-03-15

Similar Documents

Publication Publication Date Title
AR040126A1 (es) Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
AR034203A1 (es) Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento
AR044045A1 (es) Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion
AR033560A1 (es) Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento,
AR035774A1 (es) Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento
AR073760A1 (es) Derivados heterociclicos y metodos de uso de los mismos
UY27336A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
AR048302A1 (es) DERIVADOS DE PIRAZOLO-PIRIMIDINA, DE PIRAZOLO-PIRIMIDINONA, DE PIRAZOLO-PIRIDINA Y DE PIRAZOLO-PIRAZINA FUSIONADOS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA PREPARACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA CINASA P38
AR054612A1 (es) Derivados de espiroquetas y composiciones farmaceuticas para su utilizacion como agente terapeutico para diabetes
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
AR039127A1 (es) Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
AR045901A1 (es) Glucocorticoesteroides especificos con actividades antiinflamatoria y antialergica,composiciones farmaceuticas que los contienen,y procedimientos para su preparacion,
AR044011A1 (es) Antagonistas de mchr1 heterociclicos
AR032353A1 (es) Compuestos derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal y su uso en la fabricacion de medicamentos y composicion farmaceutica que los contiene
AR051294A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
AR051215A1 (es) Derivados de quinazolina
AR047703A1 (es) Derivados de quinazolina
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
AR057380A1 (es) Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento
AR045156A1 (es) Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
AR045999A1 (es) Compuesto de eter de piperidina, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para prepararlo

Legal Events

Date Code Title Description
FB Suspension of granting procedure